Form 144 LIQUIDIA CORPORATION For: 22 September
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Liquidia Corporation (LQDA)
Track the Liquidia share price today and view real-time LQDA share price data, including charts, technicals, and key financials. View the LQDA premarket stock price ahead of the market session or assess the after hours quote. Explore LQDA stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Liquidia Stock Price Today?
The Liquidia stock price today is 70.690.
What Is the Stock Symbol for Liquidia?
The stock symbol for Liquidia is ""LQDA.""
What Stock Exchange Does Liquidia Trade On?
Liquidia is listed and trades on the NASDAQ stock exchange.
Is Liquidia a Good Stock to Buy?
Determining whether Liquidia or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LQDA quote. (ISIN: US53635D2027)
What Is the Liquidia Stock Price Today?
The Liquidia stock price today is 70.690.
What Is the Stock Symbol for Liquidia?
The stock symbol for Liquidia is ""LQDA.""
What Stock Exchange Does Liquidia Trade On?
Liquidia is listed and trades on the NASDAQ stock exchange.
Is Liquidia a Good Stock to Buy?
Determining whether Liquidia or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LQDA quote. (ISIN: US53635D2027)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
68.740
73.145
52 wk Range
21.350
93.610
LQDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
68.74073.145
52 wk Range
21.35093.610
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LQDA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
107.750
Upside
+52.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Neutral
Moving Averages
Strong Buy
Analyst Ratings
6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 107.750
(+52.43% Upside)
Liquidia Corporation Earnings Call Summary for Q2/2026
- Liquidia posted Q2 2026 EPS of $0.74, missing estimates of $0.76, while revenue beat at $171.68M vs. $170.98M forecast; shares fell 4.6% to $84.
- YUTREPIA sales surged 31% sequentially to $170.4M, capturing nearly 30% of inhaled prostacyclin market share on net revenue basis.
- Company reported net income of $74.7M and adjusted EBITDA of $96.3M, marking fourth consecutive quarter of rising profitability.
- Management reaffirmed guidance for over $1B in net revenue in 2027, despite planned doubling of R&D spending in H2 2026 for L606 Phase III trial.
- Cash position strengthened to $284.2M, up $61.4M from Q1, with over 5,000 patients on therapy and 1,100+ prescribing physicians.
Last Updated: 12/08/2026, 11:38 pm
Read Full TranscriptEarnings
Latest Release
12/08/2026
EPS / Forecast
0.74 / 0.76
Revenue / Forecast
171.68M / 170.98M
Compare LQDA to Peers and Sector
Metrics to compare | LQDA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLQDAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 45.7x | −8.4x | −0.4x | |
PEG Ratio | 0.25 | −0.18 | 0.00 | |
Price/Book | 32.4x | 2.9x | 2.6x | |
Price / LTM Sales | 14.0x | 3.0x | 3.1x | |
Upside (Analyst Target) | 54.1% | 36.7% | 54.8% | |
Fair Value Upside | Unlock | 6.8% | 7.6% | Unlock |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Liquidia (LQDA) Stock Price Today?
The Liquidia stock price today is 70.690 USD.
What Stock Exchange Does Liquidia Trade On?
Liquidia is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Liquidia?
The stock symbol for Liquidia is "LQDA."
What Is the Liquidia Market Cap?
As of today, Liquidia market cap is 6.590B USD.
What Is Liquidia's Earnings Per Share (TTM)?
The Liquidia EPS (TTM) is 1.478.
When Is the Next Liquidia Earnings Date?
Liquidia will release its next earnings report on 10/11/2026.
From a Technical Analysis Perspective, Is LQDA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Liquidia Stock Split?
Liquidia has split 0 times.
How Many Employees Does Liquidia Have?
Liquidia has 216 employees.
What is the current trading status of Liquidia (LQDA)?
As of 30/09/2026, Liquidia (LQDA) is trading at a price of 70.690 USD, with a previous close of 70.690 USD. The stock has fluctuated within a day range of 68.740 USD to 73.145 USD, while its 52-week range spans from 21.350 USD to 93.610 USD.
What Is Liquidia (LQDA) Price Target According to Analysts?
The average 12-month price target for Liquidia is 107.750 USD, with a high estimate of 130 USD and a low estimate of 90 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +52.43% Upside potential.
What Is the LQDA Premarket Price?
LQDA's last pre-market stock price is 73.020 USD. The pre-market share volume is 4,600.000, and the stock has decreased by -0.650, or -0.880%.
What Is the LQDA After Hours Price?
LQDA's last after hours stock price is 71.250 USD, the stock has decreased by 0.560, or 0.790%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.